

IN THE CLAIMS:

All claims currently pending and under consideration in the referenced application are shown in the listing of claims and will replace all prior versions and listings of claims in the application. Claims 12 and 15 are amended herein. Claims 1-11, 13, 16 and 21 are cancelled herein. No new matter has been added. Please enter these claims as amended.

Listing of the Claims:

1-11. (Cancelled).

12. (Currently amended) A process for producing a cytotoxic T-cell against a minor histocompatibility antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide having up to fifteen (15) amino acids and comprising the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X represents histidine or arginine;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and

~~contacting a hematopoietic cell with the antigen presenting cell, thus, producing the cytotoxic T-cell~~

co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell resulting in stimulation of the autologous unprimed CD8+ T cell by the antigen presenting cell, thus producing the cytotoxic T-cell.

13. (Cancelled).

14. (Previously presented) The process according to claim 12, wherein the minor antigen is HA-1.

15. (Currently amended) The process according to claim 12, wherein ~~contacting the hematopoietic cell with the isolated, synthetic or recombinant peptide~~ co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell is carried out ex vivo.

16. (Cancelled).

17. (Previously presented) The process according to claim 12, wherein the cytotoxic T-cell is immortalized.

18. (Previously presented) The process according to claim 12, wherein the cytotoxic T-cell is capable of expansion.

19. (Previously presented) A cytotoxic T-cell, produced by the process according to claim 12.

20-21. (Cancelled).

22. (Previously presented) The process according to claim 12, wherein the isolated, synthetic or recombinant peptide is flanked by enzymatic cleavage sites.

23. (Previously presented) The process of claim 12 wherein the isolated, synthetic or recombinant peptide consists of SEQ ID NO:2.

24. (Previously presented) The process of claim 12 wherein the isolated, synthetic or recombinant peptide consists of SEQ ID NO:5.

25. (Previously presented) The process according to claim 12, further comprising transducing the cytotoxic T-cell with a gene that codes for herpes simplex virus thymidine kinase.

26. (New) A process for producing a cytotoxic T-cell against a minor histocompatibility antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide consisting of the amino acid sequence of SEQ ID NO:2;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and
co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell
resulting in stimulation of the autologous unprimed CD8+ T cell by the antigen presenting cell,
thus producing the cytotoxic T-cell against the minor histocompatibility antigen HA-1.

27. (New) A process for producing a cytotoxic T-cell against a minor histocompatibility
antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide consisting of the amino acid
sequence of SEQ ID NO:5;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and
co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell
resulting in stimulation of the autologous unprimed CD8+ T cell by the antigen presenting cell,
thus producing the cytotoxic T-cell against the minor histocompatibility antigen HA-1.